| Cat # | Size | Price | Quantity | |
|---|---|---|---|---|
| 631901 | 50 μg | $300 | ||
| 631902 | 500 μg | $1250 |
| Application | Bioassay |
|---|---|
| Format | Lyophilized from sterile PBS, pH 7.4. |
| Expression Host | HEK293 |
| Target Name | DLL-4, Delta-like protein 4, Dll4, hdelta2 |
| Species | Human |
| accession number | NP_061947.1 |
| Sources | A DNA sequence encoding the extracellular domain (Met1-Pro524) of human DLL4 (NP_061947.1) was expressed with the Fc region of human IgG1 at the C-terminus. |
| Molecular Weight | The recombinant human DLL4/Fc is a disulfide-linked homodimeric protein after removal of the signal peptide. The reduced monomer consists of 736 amino acids and predicts a molecular mass of 81 kDa. As a result of glycosylation, the rh DLL4/Fc monomer migrates as approximately 100-110 kDa band in SDS-PAGE under reducing conditions. |
| Affinity Tag | C-Fc |
| Purity | ≥ 95 % as determined by SDS-PAGE. ≥ 90 % as determined by SEC-HPLC. ≥ 90 % as determined by SEC-MALS(Routinely tested) |
| Regulatory Status | RUO |
| Endotoxin level | < 1.0 EU per μg protein |
| Protein Concentration | Lyophilized |
| Storage and Handling | Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles. |
Human Delta-like ligand 4 (DLL4) is a membrane-bound protein encoded by the DLL4 gene and is a critical component of the Notch signaling pathway, which regulates cell fate determination, differentiation, proliferation, and survival. DLL4 is expressed predominantly in vascular endothelial cells and plays an essential role in embryonic vascular development, angiogenesis, and maintenance of the arterial vasculature. By activating Notch receptors on adjacent cells, particularly Notch1 and Notch4, DLL4 helps coordinate endothelial cell behavior, limiting excessive blood vessel sprouting while promoting the formation of functional vascular networks.
Structurally, DLL4 is a type I transmembrane glycoprotein consisting of an extracellular domain containing a Delta/Serrate/LAG-2 (DSL) domain required for receptor binding, multiple epidermal growth factor (EGF)-like repeats that contribute to receptor specificity, a single transmembrane region, and a short intracellular cytoplasmic tail. Its principal ligands are the Notch family receptors (Notch1–4), with strongest functional interactions occurring with Notch1 and Notch4 in vascular tissues.
Aberrant DLL4 signaling has been implicated in several diseases. Overexpression is associated with tumor angiogenesis in many solid cancers, where it promotes maturation of tumor blood vessels and can contribute to resistance against anti-vascular endothelial growth factor (VEGF) therapies. Conversely, impaired DLL4 function can disrupt vascular development and has been linked to congenital cardiovascular abnormalities.
Because of its central role in regulating angiogenesis, DLL4 has emerged as an attractive therapeutic target. Monoclonal antibodies, bispecific antibodies targeting DLL4 and VEGF, and other inhibitors have been investigated as anticancer agents to induce nonproductive tumor angiogenesis and suppress tumor growth. However, systemic inhibition of DLL4 may produce vascular and hepatic toxicities, highlighting the need for carefully controlled therapeutic strategies. DLL4-targeted approaches therefore remain an active area of oncology research, with the goal of improving efficacy while minimizing adverse effects.
Recombinant human DLL4 Protein TDS
Have a product or application question? Consult our FAQs or contact us.
